Form 4: Amgen Director Michael V. Drake Receives Stock Grant

Amgen Inc. Director Michael V. Drake acquired 665 shares of common stock through an immediate vesting of Restricted Stock Units.

Summary

• Director Michael V. Drake acquired 665 shares of Amgen Inc. common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs) granted under the company's 2009 Director Incentive Program.
• Following this transaction, the director's total beneficial ownership increased to 5,774.2869 shares.
• The shares were acquired at a price of $0, reflecting the nature of an equity incentive grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity compensation practice for board members.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance and director compensation practices within the large-cap biotechnology sector, where equity-based incentives are common to ensure board alignment with long-term shareholder value.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with compensation structures at major biopharmaceutical peers such as Gilead Sciences, AbbVie, and Bristol Myers Squibb.
• Immediate vesting of director equity is a standard practice under many established equity incentive plans.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity grant to a director.

Next Steps

• None identified.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Director Compensation, Equity Incentive